Momenta Pharmaceuticals, Inc. clinical trials
Acquired by Johnson & Johnson, Oct 1, 2020 · source ↗
The registry lists 10 studies whose lead sponsor is Momenta Pharmaceuticals, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 28, 2025.
Before and after it joined Johnson & Johnson
- First submitted before Momenta Pharmaceuticals, Inc. became part of Johnson & Johnson
- 10
- First submitted after Momenta Pharmaceuticals, Inc. became part of Johnson & Johnson
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Momenta Pharmaceuticals, Inc.10 studies
Something wrong with this grouping? Tell us on the Johnson & Johnson page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Johnson & Johnson studies →
- Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) PatientsTerminatedNCT03866577Phase 1/2
Sponsor listed in the registry: Momenta Pharmaceuticals, Inc. · First submitted before Momenta Pharmaceuticals, Inc. became part of Johnson & Johnson
- An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia GravisTerminatedNCT03896295Phase 2
Sponsor listed in the registry: Momenta Pharmaceuticals, Inc. · First submitted before Momenta Pharmaceuticals, Inc. became part of Johnson & Johnson
- A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia GravisCompletedNCT03772587Phase 2
Sponsor listed in the registry: Momenta Pharmaceuticals, Inc. · First submitted before Momenta Pharmaceuticals, Inc. became part of Johnson & Johnson
- Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy SubjectsCompletedNCT02675023Phase 1
Sponsor listed in the registry: Momenta Pharmaceuticals, Inc. · First submitted before Momenta Pharmaceuticals, Inc. became part of Johnson & Johnson
- Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)CompletedNCT00543400Phase 2
Sponsor listed in the registry: Momenta Pharmaceuticals, Inc. · First submitted before Momenta Pharmaceuticals, Inc. became part of Johnson & Johnson
- An Ascending Dose Study to Evaluate M281 Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)CompletedNCT02828046Phase 1
Sponsor listed in the registry: Momenta Pharmaceuticals, Inc. · First submitted before Momenta Pharmaceuticals, Inc. became part of Johnson & Johnson
- Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type PsoriasisCompletedNCT02581345Phase 3
Sponsor listed in the registry: Momenta Pharmaceuticals, Inc. · First submitted before Momenta Pharmaceuticals, Inc. became part of Johnson & Johnson
- M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic CancerTerminatedNCT01621243Phase 1/2
Sponsor listed in the registry: Momenta Pharmaceuticals, Inc. · First submitted before Momenta Pharmaceuticals, Inc. became part of Johnson & Johnson
- Usability of an AI for M923 in Subjects With Moderate to Severe RACompletedNCT02722044Phase 3
Sponsor listed in the registry: Momenta Pharmaceuticals, Inc. · First submitted before Momenta Pharmaceuticals, Inc. became part of Johnson & Johnson
- Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy SubjectsCompletedNCT02923583Phase 1
Sponsor listed in the registry: Momenta Pharmaceuticals, Inc. · First submitted before Momenta Pharmaceuticals, Inc. became part of Johnson & Johnson